AMX0035, a fixed combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), is being developed by Amylyx Pharmaceuticals for the treatment of Amyotrophic Lateral Sclerosis (ALS). The CENTAUR trial demonstrated statistically significant efficacy in slowing functional decline in ALS patients compared to placebo, with a favorable safety profile. The ALS market is characterized by limited treatment options, and AMX0035 could position itself as a key player, particularly given the growing demand for effective therapies. Competitive analysis indicates that while there are other investigational therapies, AMX0035's unique mechanism targeting cellular death pathways may provide a differentiated value proposition. Diligence efforts should focus on regulatory pathways, potential partnerships, and market access strategies to maximize commercial potential.